Fig. 3: Prevalence of genomic alterations in tumors prior and after 1L treatment in the advanced setting. | npj Breast Cancer

Fig. 3: Prevalence of genomic alterations in tumors prior and after 1L treatment in the advanced setting.

From: CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape

Fig. 3: Prevalence of genomic alterations in tumors prior and after 1L treatment in the advanced setting.

a–d Median prevalence of alterations prior to (x-axis), or after (y-axis) treatment for a AI therapies (b) AI+CDK4/6i therapies (c) fulvestrant + CDK4/6i therapies, or d chemotherapies. Each point is an individual gene; genes of interest are labeled. Error bars represent the 95% confidence interval; Color reflects fold-change; Shape significance with an FDR cutoff of 0.2 based on bootstrapping and Benjamini-Hochberg procedure.

Back to article page